Rapporto sull’analisi delle dimensioni del mercato e dell’analisi delle quote del biotrattamento della terapia cellulare | Previsioni 2031

  • Report Code : TIPRE00021550
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 221
Buy Now

Si prevede che il biotrattamento della terapia cellulare raggiungerà i 30.052,61 milioni di dollari nel 2028 rispetto agli 11.192,50 milioni di dollari del 2020. Si stima che il mercato crescerà con un CAGR del 13,5% dal 2021 al 2028.

  ;

Il mercato del bioprocessing della terapia cellulare è stato analizzato sulla base della tecnologia, del tipo di cellula, dell'utente finale e della regione. Il mercato in base alla regione è segmentato in Nord America, Europa, Asia Pacifico, Medio Oriente e Africa, America meridionale e centrale. Il rapporto sottolinea parametri quali tendenze di mercato, progressi tecnologici, dinamiche di mercato e analisi del panorama competitivo dell'azienda leader per offrire approfondimenti e analisi approfondite del mercato del bioprocessamento della terapia cellulare. Include anche l’analisi della pandemia COVID-19 nel mercato in tutte le regioni chiave.

Regioni redditizie per il mercato del bioprocessamento della terapia cellulare

Approfondimenti di mercato

Crescenti approvazioni per le terapie cellulari

Le terapie cellulari hanno mostrato risultati positivi nel trattamento di varie malattie croniche, comprese le malattie genetiche rare, offrendo farmaci rigenerativi e farmaci personalizzati. La crescente necessità di trattare le malattie croniche ha spinto le attività di ricerca e sviluppo con conseguente aumento della produzione di terapie cellulari e delle approvazioni dei prodotti. Di seguito sono elencati alcuni esempi di approvazioni di terapie cellulari che hanno contribuito alla crescita del mercato del bioprocessing della terapia cellulare.

  • Nel maggio 2019, la Food and Drug Administration (FDA) ha approvato Zolgensma, prodotto da AveXis, Inc. Una filiale di Novartis AG. Zolgensa è progettato per trattare l'atrofia muscolare spinale nei bambini di età inferiore a due anni e viene somministrato mediante infusione una tantum in vena.
  • Nel luglio 2020, Kite Pharma, Inc., una controllata di Gilead Company, ha ricevuto la FDA approvazione per il suo Tecartus. Tecartus è una terapia con cellule T (CAR) progettata per il trattamento del linfoma a cellule del mantello refrattario (MCL) negli adulti. Secondo Gilead Company, Tecartus è la prima terapia con cellule T (CAR) approvata per il linfoma a cellule mantellari, che dovrebbe diventare una nuova frontiera nel trattamento del linfoma a cellule mantellari.
  • Nel febbraio 2021, Juno Therapeutics, Inc., una filiale della Bristol-Myers Squibb Company, ha ricevuto l'approvazione per il suo Breyanzi. Breyanzi è una terapia genica cellulare destinata al trattamento di alcuni tipi di linfoma a grandi cellule B negli adulti. Il trattamento viene somministrato dopo che il paziente non ha risposto ad almeno altri due tipi di trattamento sistemico. Tuttavia, Breyanzi nel 2019 ha dovuto affrontare una battuta d’arresto a livello normativo sin dalla sua prima presentazione; è attualmente sottoposto alla revisione dell'Agenzia europea per i medicinali ed è stato convalidato nel luglio 2020.

Pertanto, i crescenti sviluppi dei prodotti hanno portato a varie approvazioni di prodotti che riflettono l'aumento delle terapie cellulari. Pertanto, si prevede che le crescenti approvazioni per le terapie cellulari stiano aumentando enormemente il bioprocessing delle terapie cellulari, che, a sua volta, probabilmente guiderà la crescita del mercato nei prossimi anni

Approfondimenti basati sulla tecnologia

Il mercato del bioprocessing della terapia cellulare, in base alla tecnologia, è segmentato in bioreattore, liofilizzazione, elettrofilatura, centrifugazione a flusso controllato, lisi ultrasonica, tecnologia di modifica del genoma, tecnologia di immortalizzazione cellulare e vettore virale tecnologia. Il segmento Bioreactor ha detenuto la quota maggiore del mercato nel 2020, mentre si prevede che il segmento della tecnologia di editing genomico registrerà il CAGR più elevato del 14,5% nel mercato durante il periodo di previsione.

Mercato del biotrattamento della terapia cellulare, per tecnologia– 2020 e 2028

Approfondimenti basati sui tipi cellulari

Il mercato del bioprocessamento della terapia cellulare, per tipo di cellula, è segmentato in cellule staminali, cellule immunitarie, staminali embrionali umane cellula, cellula staminale pluripotente, cellule staminali emopoietiche. Il segmento delle cellule staminali ha detenuto la quota maggiore del mercato nel 2020, mentre si prevede che lo stesso segmento registrerà il CAGR più elevato del 14,0% nel mercato durante il periodo di previsione.

< p>Approfondimenti basati sull'utente finale

Il mercato del bioprocessing della terapia cellulare, per indicazione, è segmentato per malattie cardiovascolari (CVD), oncologia, guarigione delle ferite, ortopedia e altri. Il segmento oncologico ha detenuto la quota maggiore del mercato nel 2020 e si prevede che il segmento ortopedico registrerà il CAGR più elevato del 14,3% nel mercato durante il periodo di previsione.


Approfondimenti strategici

Le aziende che operano nel mercato del bioprocessing della terapia cellulare stanno adottando strategie organiche come il lancio e l'espansione di prodotti per espandere la propria presenza e il portafoglio di prodotti in tutto il mondo, nonché per soddisfare le crescenti richieste.

 

Per tecnologia

  • Bioreattore
  • Liofilizzazione
  • Elettrofilatura
  • Centrifugazione Controlflow
  • Lisi ad ultrasuoni
  • Tecnologia di modifica del genoma
  • Tecnologia di immortalizzazione cellulare
  • Tecnologia di vettori virali

Per tipo di cellula

  • Cellula staminale
  • Cellula immunitaria
  • Cellula staminale embrionale umana
  • Cellula staminale pluripotente
  • Cellula staminale ematopoietica

Per indicazione

  • Malattie cardiovascolari (CVD)
  • Oncologia
  • Guarigione delle ferite
  • Ortopedico
  • Altro

Per utente finale

  • Ospedali e cliniche
  • Centri diagnostici
  • < li>Centri di medicina rigenerativa
  • Istituto accademico e di ricerca

Per geografia

  • Nord America
    • Stati Uniti
    • Canada
    • Messico
  • Europa
    • Francia
    • Germania
    • < li>Italia
    • Regno Unito
    • Spagna
    • Resto d'Europa
  • Asia Pacifico (APAC)< ul>
  • Cina
  • India
  • Corea del Sud
  • Giappone
  • Australia
  • Resto dell'APAC< /li>
  • Medio Oriente e Africa (MEA)
    • Sudafrica
    • Arabia Saudita
    • Emirati Arabi Uniti
    • Resto del MEA
  • America centrale e meridionale (SCAM)
    • Brasile
    • Argentina
    • Resto di SCAM
  • Profili aziendali

    • Fresenius Kabi AG    ;          '   ;         
    • Asahi Kasei Corporation ;     
    • Sartorius AG                           
    • MERCK KGaA                         
    • THERMO FISHER SCIENTIFIC INC.    
    • Corning Incorporated            
    • Cytiva ;          '   ;          
    • Lonza ;          '   ;          
    • Repligen ;          '   ;       
    • Catalent Inc
    Report Coverage
    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered
    Segment Covered

    This text is related
    to segments covered.

    Regional Scope
    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope
    Country Scope

    This text is related
    to country scope.

    Frequently Asked Questions


    What are Cell Therapy Bioprocessing?

    Cell therapy bioprocessing is a subfield of bioprocess engineering that bridges cell therapy and bioprocessing (i.e., biopharmaceutical manufacturing). Cell therapy is one of the fastest-growing areas of the life sciences. It entails delivering entire living cells to a patient to treat disease.

    What are the driving factors for the Cell Therapy Bioprocessing market across the globe?

    Key factors driving the growth of the market are increasing investments for cell and gene therapy manufacturing, and growing approvals for cell therapies are the major factors driving the market growth. However, challenges such as high cost of product, regulatory challenges, and logistics challenges are likely to hinder the growth of the cell therapy bioprocessing market.

    What is the cost of Cell Therapy Bioprocessing?

    The costs of the Cell Therapy Bioprocessing are much higher, and they may cost US$ 50,000–100,000, or more, per cell therapy. The cost may also differ from product to product types.

    The List of Companies - Cell Therapy Bioprocessing Market

    1. Fresenius Kabi AG     
    2. Asahi Kasei Corporation         
    3. Sartorius AG              
    4. MERCK KGaA           
    5. THERMO FISHER SCIENTIFIC INC.              
    6. Corning Incorporated             
    7. Cytiva           
    8. Lonza            
    9. Repligen        
    10. Catalent Inc

    The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

    1. Data Collection and Secondary Research:

    As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

    Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

    1. Primary Research:

    The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

    For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

    A typical research interview fulfils the following functions:

    • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
    • Validates and strengthens in-house secondary research findings
    • Develops the analysis team’s expertise and market understanding

    Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

    • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
    • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

    Below is the breakup of our primary respondents by company, designation, and region:

    Research Methodology

    Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

    1. Data Analysis:

    Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

    • Macro-Economic Factor Analysis:

    We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

    • Country Level Data:

    Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

    • Company Profile:

    The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

    • Developing Base Number:

    Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

    1. Data Triangulation and Final Review:

    The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

    We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

    We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Related Reports